Octapharma USA Announces FDA Approval of Wilate - the First Replacement Therapy Developed Specifically for von Willebrand Disease
Links shared publicly online about this topic.
- 1,542total visits
Octapharma USA Announces FDA Approval of Wilate - the First Replacement Therapy Developed Specifically for von Willebrand Disease
Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) is used to treat von Willebrand disease (VWD). Includes Wilate side effects, interactions and indications.
View full resource at drugs.com
Tags: Disease and Condition, FDA
Most Recently Shared on December 9, 2009 at 11:29 pm By:
FDA Approves Wilate - First Replacement Therapy Developed Specifically for von Willebrand Disease - http://bit.ly/5kvip0
Advertisement
